Premium
Cost of illness of malignant lymphoma in Germany
Author(s) -
REIS A.,
IHLE P.,
PAULUS U.,
FERBER L.V.,
DIEHL V.,
WALSHE R.
Publication year - 2006
Publication title -
european journal of cancer care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 67
eISSN - 1365-2354
pISSN - 0961-5423
DOI - 10.1111/j.1365-2354.2006.00676.x
Subject(s) - medicine , lymphoma , life expectancy , indirect costs , incidence (geometry) , disease , non hodgkin's lymphoma , disease burden , environmental health , population , physics , accounting , optics , business
Cancer causes a high economic burden. The purpose of this study is to determine and compare the direct, indirect and societal costs of illness for Hodgkin’s Disease (HD), Non‐Hodgkin’s Lymphoma (NHL), Plasmocytoma and Chronic Lymphatic Lymphoma (CLL). We used a database of 1.9 million individuals enrolled in a statutory sickness fund in Germany to identify 4172 patients treated for malignant lymphoma in 2000. Direct, indirect and societal costs were calculated using a case‐control design and the human capital approach. Direct cost (in Euro) for patients with HD was 3604, for NHL patients 6149, for Plasmocytoma 8400, and for CLL patients 3226. Total indirect cost for HD was 69 million, for NHL patients 404 million, for Plasmocytoma 144 million, and for CLL patients 52 million. Totalling 1.7 billion Euro in economic cost for Germany in 2000, with 44 000 productive years lost, malignant lymphomas are a relatively costly disease group. As life expectancy increases, costs for malignant lymphoma are likely to rise due to the high prevalence among the elderly. Further research employing disaggregated, incidence‐based cost is needed.